Bristol-Myers Squibb | BMY - Current Liabilities


Bristol-Myers Squibb reported $18.66B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Abbott USD 18.38B 1.88B Mar/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Drreddys Laboratories INR 167.57B 165.8B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Medtronic USD 9.5B 440M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novo Nordisk DKK 225.16B 9.5B Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Phibro Animal Health USD 281.87M 500K Mar/2026
Prestige Brands USD 120.92M 18.63M Mar/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
Sanofi EUR 30.01B 1.66B Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Zoetis USD 2.05B 182M Mar/2026